The move marks a step in the effort to improve antibody quality as the life science community becomes increasingly aware of the problem of faulty reagents.
A group of researchers, ethicists, and others say that research into human genome editing should continue.
J. Craig Venter tells the WorldPost that humans now have the ability to control evolution, though perhaps not yet the wisdom to do it safely.
The Economist examines the potential — and possible ethical conundrums — of using CRISPR/Cas9 to edit genomes.
SeouLin Bioscience will distribute the company's cell line products in the Republic of Korea, and provide first-level technical support for local customers.
Editas Medicine raises $120 million to develop a multi-purpose gene editing approach.
The White House seeks to update how biotechnology products are regulated.
The New York Times examines ethics and China's push to lead biomedical research.
Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.
Researchers are working to bring back the American chestnut in a blight-resistant form.
The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
The US Department of Agriculture presents a new blueprint for animal genomic research.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.